Formycon Future Growth

Future criteria checks 5/6

Formycon is forecast to grow earnings and revenue by 80.8% and 23.6% per annum respectively while EPS is expected to grow by 81.3% per annum.

Key information

80.8%

Earnings growth rate

81.3%

EPS growth rate

Biotechs earnings growth	37.1%
Revenue growth rate	23.6%
Future return on equity	n/a
Analyst coverage	Low
Last updated	20 Sep 2023

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

BATS-CHIXE:FYBD - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	78	20	0	48	5
12/31/2024	58	-3	-16	7	5
12/31/2023	78	-24	-44	-15	4
6/30/2023	69	-42	-54	-17	N/A
3/31/2023	56	-3	-50	-18	N/A
12/31/2022	42	36	-46	-19	N/A
9/30/2022	38	57	-32	-17	N/A
6/30/2022	34	77	-19	-16	N/A
3/31/2022	35	32	-17	-15	N/A
12/31/2021	37	-13	-14	-13	N/A
9/30/2021	37	-15	N/A	N/A	N/A
6/30/2021	38	-15	-12	-11	N/A
3/31/2021	36	-11	-9	-8	N/A
12/31/2020	34	-7	-5	-4	N/A
9/30/2020	33	-4	N/A	N/A	N/A
6/30/2020	32	-3	12	13	N/A
3/31/2020	33	-3	5	6	N/A
12/31/2019	33	-2	-2	-1	N/A
9/30/2019	34	-2	N/A	N/A	N/A
6/30/2019	36	-1	-17	-16	N/A
3/31/2019	39	3	-2	-1	N/A
12/31/2018	43	7	12	13	N/A
9/30/2018	44	8	10	11	N/A
6/30/2018	45	9	7	8	N/A
3/31/2018	37	4	1	2	N/A
12/31/2017	29	-2	-5	-4	N/A
9/30/2017	24	-4	-4	-3	N/A
6/30/2017	19	-6	-3	-2	N/A
3/31/2017	19	-5	N/A	-4	N/A
12/31/2016	20	-4	N/A	-5	N/A
9/30/2016	18	-3	N/A	-4	N/A
6/30/2016	16	-2	N/A	-2	N/A
3/31/2016	16	-1	N/A	-1	N/A
12/31/2015	17	1	N/A	1	N/A
9/30/2015	19	0	N/A	0	N/A
6/30/2015	22	0	N/A	0	N/A
3/31/2015	17	0	N/A	0	N/A
12/31/2014	13	1	N/A	0	N/A
12/31/2013	0	-8	N/A	-17	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: FYBD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.4%).

Earnings vs Market: FYBD is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: FYBD is expected to become profitable in the next 3 years.

Revenue vs Market: FYBD's revenue (23.6% per year) is forecast to grow faster than the UK market (4% per year).

High Growth Revenue: FYBD's revenue (23.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if FYBD's Return on Equity is forecast to be high in 3 years time

Formycon Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Forecast breakeven date pushed back to 2023

Formycon AG Provides Revenue Guidance for the Year 2021

Formycon AG Provides Sales Guidance for the Fiscal Year 2021

Recent updates

Formycon AG Appoints Colin Bond as Director

Fresenius Kabi and Formycon Receives U.S. FDA Approval for Biosimilar Otulfi (ustekinumab-aauz)

Formycon AG to Report First Half, 2024 Results on Aug 13, 2024

Formycon AG to Report Q1, 2024 Results on May 08, 2024

Formycon AG to Report Fiscal Year 2023 Final Results on Apr 25, 2024

Formycon AG has completed a Follow-on Equity Offering in the amount of €82.840247 million.

Formycon AG to Report First Half, 2023 Results on Aug 30, 2023

Formycon Announces Submission of the Biologics License Application (Bla) for Fyb203, an Aflibercept Biosimilar Candidate to the U.S. Food and Drug Administration (Fda)

Full year 2022 earnings released: EPS: €2.62 (vs €1.22 loss in FY 2021)

Formycon AG has completed a Follow-on Equity Offering in the amount of €70.07 million.

Formycon AG Publishes Details of A Previously Undisclosed Pipeline Project – Fyb206 Is A Biosimilar Candidate for Keytruda (Pembrolizumab)

Formycon AG, Polpharma Biologics Group BV and Bioeq AG Announce European Commission Approval for FYB201/Ranivisio1 (Ranivisio - Ranibizumab), a Biosimilar to Lucentis2 (News with Additional Features)

Formycon Ag Announces EU-Approval of FYB201/Ranivisio A Biosimilar to Lucentis

Formycon's Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product Stelara in Phase III Study

Formycon Announces FDA Approval of Fyb201/Cimerlitm1 (Ranibizumab-EQRN) as A Biosimilar Interchangeable with Lucentis®2

Formycon AG Announces Supervisory Board and Executive Changes

Formycon's Biosimilar for Lucentis (Ranibizumab), Receives CHMP Recommendation from EMA

Forecast breakeven date pushed back to 2023

Formycon AG Announces Changes to Its Executive Board

Formycon AG Announces Receipt of Market Authorization of from Medicines and Healthcare Products Regulatory Agency

Formycon AG Provides Revenue Guidance for the Year 2021

Formycon AG and Bioeq AG Announce Submits Biologics License Application for FYB201 to U.S. Food and Drug Administration

Formycon AG Provides Sales Guidance for the Fiscal Year 2021

Formycon Receives Approval for Early Action for COVID-19 Drug FYB207 as Part of a Grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy

Formycon Receives Positive Scientific Advice from Paul-Ehrlich-Institute for the COVID-19 Drug FYB207 and Assures GMP Manufacturing Capacities

Formycon AG, Annual General Meeting, Sep 27, 2021

Formycon's Scientific Collaboration Partners Present FYB207 Results At International Keystone Symposium

New 90-day high: €47.00

Formycon AG and Bioeq GmbH Announce Launch of Phase III Study of FYB202, a Biosimilar Candidate for Stelara(R) (Ustekinumab)

Formycon AG and Bioeq AG Announce Biologics License Application Resubmission Strategy for Fyb201 Has Been Adjusted

Formycon AG to Report Q1, 2020 Results on Jun 22, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies